James Peyer
@JamesPeyer
Followers
4K
Following
2K
Media
60
Statuses
912
CEO @cambrianbio | PhD | creating medicines to keep people healthy | opinions my own
New York, USA
Joined June 2014
We need to draw a distinction between: mitochondrial dysfunction (i.e., the mitochondria being less able to produce ATP, which declines a little with aging) and mitochondrial activation (i.e., the signals that tell the mitochondria to turn on [eg: AMPK], which declines a lot)
As a postdoc the (Great) Ben Barres, MD, PhD (alas now deceased from cancer) used to stop me at least once a week & say/shout “why do we have less energy as we age?! It’s NOT mitochondria! Someone has to figure this out! Why is no one working on this?!” What do you think?
0
0
5
This Sunday, 7/13‼️Our CEO @JamesPeyer is headed to @TheEndoSociety to present new data on the efficacy of ATX-304, our lead drug. Check out the press release to learn more 👇 https://t.co/dykERwYSwT
0
1
5
Come see the presentation on Sunday if you're around. It's fun to be able to show off some of the data that we've been keeping in the hopper for such a long time waiting for the right time to go live with it =) More info here ⬇️ https://t.co/iREXj6gzue
2
2
3
- drive weight loss without muscle loss - enable faster weight loss in combination with semaglutide with complete protection from muscle loss - prevent weight regain in animals that come off semaglutide All by boosting metabolic activity with no effect on food intake.
3
1
5
This weekend I'm headed to the @TheEndoSociety conference in SF where we've been invited to give an oral presentation. I’ll be sharing with the world for the first time the ability of our lead drug, ATX-304 to 🧵👇
2
1
9
Mark your calendars! Our Founder and CEO @celinehalioua is joining @JamesPeyer and @AlexLJanin on stage at the @WSJ's Future of Everything next Wednesday, May 28 for a wide-ranging conversation about longevity drug development and the future of preventive medicine.
2
3
14
@DKThomp & @ezraklein was prompted by reading your book to put some thoughts down on how the Abundance Framework could make drugs for aging that you mention a few times come about faster and with higher probability https://t.co/q9toIaqa6Z
0
0
4
Early bird registration for the 2025 Keystone on Aging and Gerotherapeutics ends today! The amazing speaker lineup includes @BrunetLab @BBParis1984 @gio_SiGa @dariovalenzano_ @DrMorganLevine @mkaeberlein
https://t.co/5tkDX6Pvxc
keystonesymposia.org
Join us at the Keystone Symposia on Aging: New Frontiers in Rejuvenation and Gerotherapeutics, February 2025, in Breckenridge, with field leaders!
1
8
17
BioAge is now a public company! I'm incredibly proud of our team and grateful to our partners and investors who made this possible. By targeting the biology of aging, we're developing therapies to tackle metabolic diseases and change lives. Excited for what's ahead!
We are thrilled to announce the closing of BioAge's IPO! As of September 26, we are trading on Nasdaq as $BIOA. This milestone will enable our development of novel therapies that treat metabolic diseases by harnessing the biology of aging. (1/3)
30
32
357
Congratulations @kpfortney and team @bioagelabs! Kristen & her team have successfully navigated a tough time in biotech. We're really looking forward to the readout of the azelaprag + GLP trials. Healthy treatment of obesity is the lowest hanging fruit of preventative medicine
We are thrilled to announce the closing of BioAge's IPO! As of September 26, we are trading on Nasdaq as $BIOA. This milestone will enable our development of novel therapies that treat metabolic diseases by harnessing the biology of aging. (1/3)
0
1
14
7.5kg weight loss is a lot. Inverse munchies.
$NVO monlunabant CB1 results: "Reporting of mild to moderate neuropsychiatric side effects, primarily anxiety, irritability, and sleep disturbances, was more frequent and dose dependent with monlunabant compared to placebo. No serious adverse events were reported in relation to
0
0
1
GLPs opening the door for interventions that really work to prevent major age-related diseases may end being one of the most important shift in healthcare this century. The Lasker is well deserved.
Three scientists involved in developing the blockbuster anti-obesity drugs that are currently changing the health-care landscape are among the winners of this year’s prestigious Lasker Awards
0
3
10
A large number of people with high BMI are metabolically healthy, so it's certainly not a perfect biomarker, but it's also easy to measure and pretty good in most cases.
1
1
1
Nuance is hard, and I appreciate @nytimes for trying to thread the needle. Obesity is a risk factor for multiple diseases. It is a biomarker. Obesity plus other morbidities is a disease. https://t.co/qC1g2Gbi1U
nytimes.com
Experts are rushing to redefine obesity amid soaring demand for new weight-loss drugs.
1
2
5
A provocative and clever question. The door that opens once we have the first Phase 3 clinical data with a drug showing multi-disease prevention by an average of 36 months would be massive. Would create a race for innovation in the field.
What do you think would be a more impactful result for the field of aging biology? 1.) A clinical trial that shows that a geroprotector works and delays disease onset by 3 years. 2.) A preclinical study that shows that maximum mouse lifespan has been doubled?
1
2
10
12pm ET today for members of the @LBA_longevity - chatting with @j_n_justice of @xprize "Everything you wanted to know about The X Prize" Stop into the virtual roundtable if you're a member. These have been a great series of small meetings for the community.
12
0
4
This monument in Novosibirsk, southwestern Siberia, honors the humble lab mouse and the important role mice have played in science. Unveiled in 2013, the quirky statue depicts an anthropomorphic mouse as an elderly woman, complete with glasses balanced atop its nose. Emerging
12
39
234
Beautiful illustration of the maxim that zip code is the biggest predictor of life expectancy today.
3
0
4
@levie @elonmusk Part of the misunderstanding of drug pricing is the impact of pharmacy benefit managers. Prior to @costplusdrugs publishing our price list, there was not a benchmark to compare prices. They made sure that every contract was opaque and under an NDA For instance, Box, Tesla,
60
169
1K